The civic record
Read. Follow. Verify.Arizona Senate Bill 1542 appropriates $10 million for PTSD clinical trials using midomafetamine and…
Last action · February 18, 2026: DPSponsor: Kevin Payne
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
What This Bill Proposed
Senate Bill 1542 appropriates $10 million in 2026-2027 to the Arizona Department of Health Services for grants supporting clinical trials, research, and clinician training on using to treat post-traumatic stress disorder in first responders and veterans. The bill also conditionally requires employers to provide workers' compensation coverage for one complete course of midomafetamine treatment for firefighters and certified peace officers diagnosed with PTSD, provided federal approval is granted by January 1, 2029.
Sets up state-funded research grants and potential insurance coverage rules for a specific psychedelic-assisted therapy for post-traumatic stress disorder, affecting state mental health budgets, public safety employers, and specialized medical researchers.
Who It Would Have Affected
Groups the bill's text would have affected, as described in the record. Being affected is not a position for or against it.
Firefighters
Professional firefighters diagnosed with PTSD may become eligible for workers' compensation coverage including one complete course of midomafetamine treatment if federal approval conditions are met.
Certified peace officers
Certified peace officers diagnosed with PTSD may become eligible for workers' compensation coverage including one complete course of midomafetamine treatment if federal approval conditions are met.
Arizona Department of Health Services
The department receives a $10,000,000 appropriation in fiscal year 2026-2027 to administer grant awards for clinical trials, research, and clinician training.
Public institutions of higher education
Public universities in Arizona delivering mental health care or clinical research may apply as lead applicants or partners for grant funding under the bill.
Key Facts
You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.
Frequently Asked Questions
Who is eligible to receive workers' compensation coverage for midomafetamine treatment under this bill?
What is the purpose of the $10 million appropriation in the bill?
Are the provisions in this bill effective immediately?
What else do you want to know?
News Coverage
Follow the record
Votes, people, money & the original sourceWhere This Stands
This bill did not become law - Died at adjournment · in Senate committee.
Procedural history
3 actions- Feb 18, 2026SenateCommitteeDP
- Feb 3, 2026SenateFloorSenate Second Reading
- Feb 2, 2026SenateIntroducedSenate First Reading
Version history
Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.
View official text →Lobbying Activity
No state lobbying filings in our records match this bill. Federal lobbying reports (LDA) cover Congress, so they are not listed on state bills.
Full breakdown
Who this bill affects and the strongest case for and against it, written only from the bill’s own text.
Sponsors
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Conditional Psychedelic Therapy Coverage
The measure ties state workers' compensation coverage and controlled substance rescheduling directly to future federal FDA approval milestones for midomafetamine.
Connected Entities
Sources
apps.azleg.gov
Analysis Score
0–100- Significance20Lowered because this bill did not pass (its text scored 75)
- Controversy45Intensity of disagreement among stakeholders
- Entertainment15Compellingness for a non-policy-wonk reader
- Buzz50Current news / social attention level
Publisher tools
